Clinical Trials Logo

Clinical Trial Summary

Lesions classified as "High Grade Squamous Intra-epithelial Lesions" (HSIL) are pre-cervical lesions of the cervix, induced by infection with the Human Papilloma Virus (HPV). The detection and proper management of these lesions greatly reduces the incidence of invasive cervical cancer. Pap smear remains the most effective tool for early detection of low and high-grade cervical lesions. In Belgium, screening for cervical cancer is recommended every 3 years for women between 25 and 65 years old. HPV is a virus who possesses certain oncogenic genes who have the ability to inactivate tumor suppressor genes in the host cell. This promotes a tumorigenesis process within the tissues affected by the virus. The majority of human papillomavirus infections are transient and spontaneously cleared by host defense mechanisms, especially in the first two years after exposure. However, 10-20% of infections persist latently and may eventually lead to progression to invasive cervical cancer. Even high-grade lesions kan naturally be cleared, even more so if the patient is young and immuno-competent. Therefore, the management of HSIL lesions in young women has been modified and consists of adopting mainly a conservative attitude, with controls every 6 months for 2 years. This management makes it possible to avoid unnecessary conizations of the cervix which, in young nulliparous patients, are not devoid of heavy obstetric consequences during subsequent pregnancies (premature birth, perinatal mortality). Cervical conization will only be considered for lesions that progress during follow-up or that persist beyond 2 years. However, this type of follow-up requires that patients be compliant. Our study has two main objectives: - to determine the compliance of CHU Brugmann Hospital patients who have been proposed a conservative strategy for the management of HSIL lesions. - to identify the predictive factors for the persistence and / or progression of high-grade pre-cancerous dysplastic lesions.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03920800
Study type Observational
Source Brugmann University Hospital
Contact
Status Completed
Phase
Start date March 1, 2019
Completion date November 20, 2019

See also
  Status Clinical Trial Phase
Completed NCT04177641 - Evaluation of Thioldisulfide Balance in Cervical Preinvasive Lesions
Recruiting NCT05210348 - Clinical Evaluation of Detection of High Risk HPV in Urine
Not yet recruiting NCT04115787 - Conservative Management in Patients Diagnosed With Grade 2 or Grade 3 CIN
Completed NCT06325592 - Association Between Surgical Timing and Route of Total Hysterectomy After LEEP and Perioperative Risk in Patients With Cervical HSIL
Active, not recruiting NCT02576561 - Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL Phase 2
Active, not recruiting NCT05613283 - Primary Cervical Cancer Screening by Self-sampling HPV Test
Not yet recruiting NCT06333743 - Laser Ablation in the Treatment of High-grade Cervical Lesions N/A
Not yet recruiting NCT06233331 - Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV Phase 1
Completed NCT03239223 - Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection Phase 1